# Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone

Source: https://onco.cc/trials/nct03040973/  
OnCo record `nct03040973` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Capmatinib, Gefitinib and Osimertinib in advanced solid tumours, run by Novartis Pharmaceuticals, active and no longer recruiting.

## Summary

Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone is a phase 2 interventional study registered as NCT03040973 by Novartis Pharmaceuticals, with 29 participants enrolled, started 2017-07-04 and due to reach its primary completion in 2027-07-30. Interventions recorded: Capmatinib, Nazartinib, Gefitinib and Osimertinib.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03040973
- Phase: 2
- Setting: An Open-label, Multi-center, Global, Rollover Study for Patients Who Have Previously Been Treated With Capmatinib (INC280) as Monotherapy or in Combination in a Novartis Sponsored Trial.
- Sponsor: Novartis Pharmaceuticals
- Enrolled: 29

## Sources

- ClinicalTrials.gov NCT03040973: https://clinicaltrials.gov/study/NCT03040973

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Capmatinib](https://onco.cc/drugs/capmatinib/), [Gefitinib](https://onco.cc/drugs/gefitinib/), [Osimertinib](https://onco.cc/drugs/osimertinib/)
- companies: [Advanced Accelerator Applications (Novartis)](https://onco.cc/companies/advanced-accelerator-applications/)

---
JSON: https://onco.cc/api/v1/entities/nct03040973.json